首页 | 本学科首页   官方微博 | 高级检索  
检索        

GP方案与NP方案治疗非小细胞肺癌疗效及药物经济学评价
引用本文:庞丹梅,罗平,唐溢聪,梁剑苗.GP方案与NP方案治疗非小细胞肺癌疗效及药物经济学评价[J].肿瘤研究与临床,2006,18(5):329-331.
作者姓名:庞丹梅  罗平  唐溢聪  梁剑苗
作者单位:528041,广东省佛山市第一人民医院肿瘤医院内科
摘    要:  目的 比较吉西他滨加顺铂(GP方案)与长春瑞滨加顺铂(NP方案)两种联合方案治疗晚期非小细胞肺癌(NSCLC)的疗效、毒副反应及药物经济学评价。方法 用GP方案治疗晚期NSCLC 39例(GP组)与NP方案治疗晚期NSCLC 37例(NP组),统计分析临床资料。结果 GP组有效率48.7 %,NP组有效率45.9 %,两组疗效差异无统计学意义(P>0.05),毒副反应主要为恶心呕吐、骨髓抑制。NP组的静脉炎较GP组多发,GP组血小板减少及皮疹发生率高于NP组,GP组的疾病进展时间较NP组延长(P<0.05)。2疗程平均药物费用GP组¥(23 664±384.7)元,NP组¥(8519.94±369.1)元,有效率与所需费用之比GP组¥(485.02±34.65)元,NP组¥(185.62±23.77)元,中位生存期与所需费用之比GP组¥(2211.59±59.15)元,NP组¥(946.66±43.3)元,1年生存率与所需费用之比GP组¥(608.33±14.35)元,NP组¥(243.43±21.57)元。药物费用NP组明显低于GP组,费用疗效比NP组优于GP组(P<0.05)。结论 两种方案均为治疗晚期NSCLC的一线方案,在治疗晚期NSCLC时可选用。

关 键 词:吉西他滨  顺铂  长春瑞滨  非小细胞肺癌
文章编号:1006-9801(2006)05-0329-03
收稿时间:2005-06-24
修稿时间:2006-01-10

Comparative study of gemcitabine and cisplatin versus navelbine and cisplatin in the treatment of advanced non-small-cell lung cancer
PANG Dan-mei,LUO Ping,TANG Yi-cong,LIANG Jian-miao.Comparative study of gemcitabine and cisplatin versus navelbine and cisplatin in the treatment of advanced non-small-cell lung cancer[J].Cancer Research and Clinic,2006,18(5):329-331.
Authors:PANG Dan-mei  LUO Ping  TANG Yi-cong  LIANG Jian-miao
Institution:Department of Medical Oncology, the First People's Hospital of Foshan City
Abstract:Objective To compare the efficacy and toxicity of two new platinum-based chemothera-peutic regimens for advanced non-small-cell lung cancer (NSCLC), and to evaluate the two chemotherapeutic regimens by pharmacocconomic analysis. Methods The clinical data of 76 cases with advanced NSCLC treated with (1) gemcitabine plus cisplatin (GP group, 39cases), (2) navelbine plus cisplatin (NP group, 37cas-es) and were analysed. Results The response rate was 48.7 % in patients treated with GP, 46.9 % in those treated with NP respectively (P > 0.05). The major toxic reactions in the two groups was tolerable myelo-sup-pression. The average cost of one patient for two therapeutic cycles was ¥(23664±384.7) and ¥(8519.94±369.1) respectively. Escalation of 1 % of response rate costed ¥(485.02±34.65) and ¥(185.62±23.77) respectively. Prolongation of 1 month of median survival duration costed ¥(2211.59±59.1) and ¥(946.66±43.3) respectively.TTP in group GP is longer than that in group NP(P<0.05). Conclusion GP and NP are effective and safe chemotherapeutic protocols for the treatment of advanced NSCLC patients. The expenditure of NP is much cheaper than GP. They could be considered as a selective treatment regimen.
Keywords:Gemcitabine  Cisplatin  Navelbine  Non-small-cell lung cancer
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《肿瘤研究与临床》浏览原始摘要信息
点击此处可从《肿瘤研究与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号